- Home
- ACIC vs SRDX Comparison
ACIC vs SRDX Comparison
Compare ACIC & SRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- SRDX
- Stock Information
- Founded
- ACIC 1999
- SRDX 1979
- Country
- ACIC United States
- SRDX United States
- Employees
- ACIC N/A
- SRDX N/A
- Industry
- ACIC Property-Casualty Insurers
- SRDX Medical/Dental Instruments
- Sector
- ACIC Finance
- SRDX Health Care
- Exchange
- ACIC Nasdaq
- SRDX Nasdaq
- Market Cap
- ACIC 556.0M
- SRDX 457.0M
- IPO Year
- ACIC N/A
- SRDX 1998
- Fundamental
- Price
- ACIC $11.13
- SRDX $31.91
- Analyst Decision
- ACIC Buy
- SRDX Buy
- Analyst Count
- ACIC 1
- SRDX 3
- Target Price
- ACIC $16.00
- SRDX $43.00
- AVG Volume (30 Days)
- ACIC 169.5K
- SRDX 230.7K
- Earning Date
- ACIC 11-05-2025
- SRDX 11-05-2025
- Dividend Yield
- ACIC 4.45%
- SRDX N/A
- EPS Growth
- ACIC 14.01
- SRDX N/A
- EPS
- ACIC 1.63
- SRDX N/A
- Revenue
- ACIC $320,072,000.00
- SRDX $120,801,000.00
- Revenue This Year
- ACIC $4.91
- SRDX N/A
- Revenue Next Year
- ACIC $4.16
- SRDX $3.38
- P/E Ratio
- ACIC $6.88
- SRDX N/A
- Revenue Growth
- ACIC 33.90
- SRDX N/A
- 52 Week Low
- ACIC $8.82
- SRDX $26.00
- 52 Week High
- ACIC $15.08
- SRDX $40.39
- Technical
- Relative Strength Index (RSI)
- ACIC 53.71
- SRDX 36.39
- Support Level
- ACIC $10.71
- SRDX $31.20
- Resistance Level
- ACIC $11.17
- SRDX $32.50
- Average True Range (ATR)
- ACIC 0.35
- SRDX 0.87
- MACD
- ACIC -0.02
- SRDX -0.26
- Stochastic Oscillator
- ACIC 43.90
- SRDX 19.92
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About SRDX Surmodics Inc.
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.